Logo image of AGIO

AGIOS PHARMACEUTICALS INC (AGIO) Stock Fundamental Analysis

USA - NASDAQ:AGIO - US00847X1046 - Common Stock

37.7 USD
-0.25 (-0.66%)
Last: 9/19/2025, 8:00:00 PM
37.7 USD
0 (0%)
After Hours: 9/19/2025, 8:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to AGIO. AGIO was compared to 541 industry peers in the Biotechnology industry. While AGIO has a great health rating, there are worries on its profitability. AGIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AGIO had negative earnings in the past year.
AGIO had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: AGIO reported negative net income in multiple years.
In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

Looking at the Return On Assets, with a value of 44.19%, AGIO belongs to the top of the industry, outperforming 99.45% of the companies in the same industry.
AGIO's Return On Equity of 47.47% is amongst the best of the industry. AGIO outperforms 98.71% of its industry peers.
Industry RankSector Rank
ROA 44.19%
ROE 47.47%
ROIC N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGIO has a Profit Margin of 1590.42%. This is amongst the best in the industry. AGIO outperforms 99.63% of its industry peers.
AGIO has a better Gross Margin (88.18%) than 89.83% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1590.42%
GM 88.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

9

2. Health

2.1 Basic Checks

AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGIO has more shares outstanding
Compared to 5 years ago, AGIO has less shares outstanding
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 12.36 indicates that AGIO is not in any danger for bankruptcy at the moment.
AGIO has a better Altman-Z score (12.36) than 87.80% of its industry peers.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.36
ROIC/WACCN/A
WACC9.66%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

AGIO has a Current Ratio of 14.48. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AGIO (14.48) is better than 88.91% of its industry peers.
A Quick Ratio of 14.04 indicates that AGIO has no problem at all paying its short term obligations.
The Quick ratio of AGIO (14.04) is better than 88.35% of its industry peers.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.04
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

AGIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.86%.
The earnings per share for AGIO have been decreasing by -24.03% on average. This is quite bad
AGIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.56%.
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
Revenue 1Y (TTM)30.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%

3.2 Future

Based on estimates for the next years, AGIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.93% on average per year.
Based on estimates for the next years, AGIO will show a very strong growth in Revenue. The Revenue will grow by 92.49% on average per year.
EPS Next Y-7.73%
EPS Next 2Y-2.83%
EPS Next 3Y8.1%
EPS Next 5Y16.93%
Revenue Next Year25.97%
Revenue Next 2Y75.19%
Revenue Next 3Y97.75%
Revenue Next 5Y92.49%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.83%
EPS Next 3Y8.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (9/19/2025, 8:00:00 PM)

After market: 37.7 0 (0%)

37.7

-0.25 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners104.08%
Inst Owner Change-0.85%
Ins Owners0.85%
Ins Owner Change0.92%
Market Cap2.19B
Analysts78.57
Price Target49.57 (31.49%)
Short Float %8.64%
Short Ratio5.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.06%
Min EPS beat(2)-4.68%
Max EPS beat(2)14.81%
EPS beat(4)2
Avg EPS beat(4)-71.89%
Min EPS beat(4)-314.16%
Max EPS beat(4)16.46%
EPS beat(8)4
Avg EPS beat(8)-34.24%
EPS beat(12)8
Avg EPS beat(12)-7.97%
EPS beat(16)11
Avg EPS beat(16)-5.1%
Revenue beat(2)1
Avg Revenue beat(2)8.78%
Min Revenue beat(2)-11.26%
Max Revenue beat(2)28.81%
Revenue beat(4)2
Avg Revenue beat(4)5.81%
Min Revenue beat(4)-11.26%
Max Revenue beat(4)28.81%
Revenue beat(8)2
Avg Revenue beat(8)-0.72%
Revenue beat(12)4
Avg Revenue beat(12)-3.31%
Revenue beat(16)5
Avg Revenue beat(16)-11.5%
PT rev (1m)-6.54%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.54%
Revenue NY rev (1m)-3.53%
Revenue NY rev (3m)1.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 53.59
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-7.34
EYN/A
EPS(NY)-7.4
Fwd EYN/A
FCF(TTM)-7.04
FCFYN/A
OCF(TTM)-6.99
OCFYN/A
SpS0.7
BVpS23.57
TBVpS23.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 44.19%
ROE 47.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1590.42%
GM 88.18%
FCFM N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.67%
Cap/Sales 7.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.48
Quick Ratio 14.04
Altman-Z 12.36
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)33.97%
Cap/Depr(5y)62.68%
Cap/Sales(3y)14.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
EPS Next Y-7.73%
EPS Next 2Y-2.83%
EPS Next 3Y8.1%
EPS Next 5Y16.93%
Revenue 1Y (TTM)30.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%
Revenue Next Year25.97%
Revenue Next 2Y75.19%
Revenue Next 3Y97.75%
Revenue Next 5Y92.49%
EBIT growth 1Y-13.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.47%
EBIT Next 3Y6.71%
EBIT Next 5YN/A
FCF growth 1Y-36.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.6%
OCF growth 3YN/A
OCF growth 5YN/A